CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

BLD-2660Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug452 Ketamine Wiki 1.00
drug537 Naltrexone Wiki 1.00
drug616 Placebo Wiki 0.10

Correlated MeSH Terms (6)

Name (Synonyms) Correlation
D055371 Acute Lung Injury NIH 0.16
D013577 Syndrome NIH 0.15
D012127 Respiratory Distress Syndrome, Newborn NIH 0.15
D012128 Respiratory Distress Syndrome, Adult NIH 0.13
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment

BLD-2660 is a novel, synthetic, orally active, small molecule inhibitor of calpain (CAPN) 1, 2, and 9 that is selective over the cathepsins as well as other protease families, displays good metabolic stability and permeability, oral bioavailability and low cytochrome P450 (CYP) inhibition. It is under development for the treatment of coronavirus disease-19 (COVID-19) resulting from infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2), where there is significant unmet medical need.

NCT04334460 Sars-CoV2 Drug: BLD-2660

Primary Outcomes

Description: To evaluate antiviral activity of BLD2660 in hospitalized adults with recently diagnosed SARS-CoV-2 infection. Measured by quantity of remaining viral RNA of SARS-CoV-2 qPCR Assay and proportion of subjects who are SARS-CoV-2-free by Day 10/End of treatment (EOT) or hospital discharge, whichever is sooner

Measure: Antiviral Activity

Time: Course of study; 21 days

Description: To evaluate improvement in oxygenation in hospitalized adults with COVID-19 treated with BLD-2660. Measured by change from baseline to Day 10 or hospital discharge, if sooner, in the ratio of peripheral hemoglobin oxygen saturation to fraction of inspired oxygen (SpO2/FiO2)

Measure: Improvement of oxygenation

Time: 10 days

Secondary Outcomes

Description: To evaluate the safety and tolerability of BLD-2660 in the same population. Measured by incidence of TEAEs and serious adverse events (SAEs)

Measure: Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs)

Time: Course of study; 21 days

Other Outcomes

Description: To evaluate intervention's effects on length of hospital stay.

Measure: Time to hospital discharge

Time: Course of study; 21 days

Description: Proportion of subjects with resolution of fever below entry criteria for 24 hours (as defined in Section 5.1.1) by Day 10 in subjects with fever at baseline

Measure: Resolution of Fever

Time: Course of study; 21 days

Description: Number of continuous O2 supplementation free days during the 10-day,14-day and 21-day study periods following enrollment

Measure: Oxygen Supplementation-Free Days

Time: Course of Study; 21 days

Description: Change from baseline to Days 10, 14 and 21 in IL-6, measured by quantitative assay.

Measure: Change in IL-6

Time: Course of study; 21 days

No related HPO nodes (Using clinical trials)